TY - JOUR
T1 - Toward an effective peripheral visceral analgesic
T2 - Responding to the national opioid crisis
AU - Camilleri, Michael
N1 - Funding Information:
M. Camilleri reports research support from Allergan for a study involving eluxadoline.
Funding Information:
This work was funded by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK-115950.
Publisher Copyright:
© 2018 the American Physiological Society.
PY - 2018/6
Y1 - 2018/6
N2 - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.
AB - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.
KW - Cannabinoid
KW - Estrogen
KW - Receptors
KW - Transient receptor potential
UR - http://www.scopus.com/inward/record.url?scp=85048218115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048218115&partnerID=8YFLogxK
U2 - 10.1152/ajpgi.00013.2018
DO - 10.1152/ajpgi.00013.2018
M3 - Short survey
C2 - 29470146
AN - SCOPUS:85048218115
VL - 314
SP - G637-G646
JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
SN - 1931-857X
IS - 6
ER -